Close
Smartlab Europe
Inizio Ignite

Industry Reports

WestRock to acquire Multi Packaging Solutions for total enterprise value of $2.28 bln

WestRock Company and Multi Packaging Solutions International Limited announced that a definitive agreement has been reached for WestRock to acquire all of the outstanding shares of MPS for $18.00 per share in cash and the assumption of an estimated...

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion...

OncoGenex Pharmaceuticals and Achieve Life Science Announce Definitive Merger Agreement

OncoGenex Pharmaceuticals, Inc , a publicly held oncology biopharmaceutical company, and Achieve Life Science, Inc , a privately held specialty pharmaceutical company, announced that they have entered into a definitive merger agreement under which OncoGenex will acquire Achieve in...

Factor One Source Pharmacy to Acquire F.A.S.T. Access Rx

Factor One Source Pharmacy and Fast Access Specialty Therapeutics announced today that they have entered into a definitive agreement under which FOSRx will acquire F.A.S.T. for a combination of cash and stock. Together the two companies...

Moberg pharma completes acquisition of dermoplast of prestige brands

Moberg Pharma AB has now completed the acquisition of DermoPlast® Prestige Brands, Inc. in accordance with the terms announced on December 6. The purchase price was 47.6 million plus inventory value. DermoPlast® is a topical spray...

Global Drug Market Will Reach Nearly $1.5 Trillion in 2021

Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33 percent from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released by the...

Novartis announces phase II SUSTAIN study of SEG101 significantly reduces frequency of sickle cell pain crises

Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) in patients with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »